Supreme Court Flags Wide Price Differences
Supreme Court Questions Gaps in India’s Medicine Pricing System: The Supreme Court of India has raised serious concerns over the large difference between the Price To Retailer (PTR) and the printed Maximum Retail Price (MRP) of medicines. A bench comprising Justice Vikram Nath and Justice Sandeep Mehta questioned whether such large markups can be justified when patients depend on medicines for essential treatment.
The Court referred to an example in which an essential cancer medicine was reportedly supplied to a retailer for around ₹2,700, while its MRP was nearly ₹27,000. The ten-fold difference prompted the bench to question why such disparities should be permitted within the existing pricing framework.
The proceedings involve petitions seeking stronger regulation of medicine prices, generic medicines, medical devices and prescription practices. The Court has particularly examined whether the existing framework adequately protects patients from excessive pricing.
DPCO and Retailer Margin
The Drugs (Prices Control) Order, 2013 (DPCO) is a major instrument used by the Union Government to regulate pharmaceutical prices. For scheduled formulations, the ceiling-price mechanism includes a 16% retailer margin while calculating the permissible price.
The Supreme Court has questioned why a similar approach should not apply more broadly to essential medicines where substantial differences exist between PTR and MRP. The issue is particularly significant for medicines used in serious and long-term treatments.
Static GK fact: The DPCO operates under the Essential Commodities Act, 1955, which empowers the government to regulate production, supply, distribution and prices of essential commodities.
Role of NPPA
The National Pharmaceutical Pricing Authority (NPPA) was established in 1997 under the Department of Pharmaceuticals. It is responsible for implementing and enforcing pharmaceutical price-control provisions.
The NPPA fixes or revises ceiling prices of scheduled formulations, monitors overcharging and can initiate recovery of amounts charged beyond permissible prices. The framework also provides for regulation of certain new drugs and exceptional price interventions.
Scheduled and Non Scheduled Medicines
A key concern before the Court is the distinction between scheduled and non-scheduled medicines. Scheduled formulations fall within the price-control mechanism, whereas manufacturers generally have greater freedom when initially pricing non-scheduled medicines.
The petitions have argued that this gap can allow manufacturers to establish a high initial price before subsequent restrictions become applicable. The Court is examining whether the existing distinction adequately serves the objective of affordable medicines.
Static GK Tip: The First Schedule of the DPCO contains medicines covered by the scheduled price-control framework, with ceiling prices determined using market-based pricing principles.
Impact on Patients and Public Spending
High medicine prices can affect both individual patients and publicly funded healthcare programmes. The Supreme Court has also highlighted the concern that when expensive medicines are reimbursed under government health schemes, inflated prices can ultimately increase the burden on public funds and taxpayers.
The broader debate therefore involves balancing pharmaceutical industry interests, retailer economics, availability of medicines and the need for affordable healthcare.
Need for Stronger Price Regulation
The case places the spotlight on transparency in medicine pricing, regulation of margins and the effectiveness of existing enforcement mechanisms. Any future policy response will need to consider affordability while maintaining incentives for pharmaceutical production, innovation and availability.
Static Usthadian Current Affairs Table
Supreme Court Questions Gaps in India’s Medicine Pricing System:
| Fact | Detail |
| Supreme Court Bench | Justice Vikram Nath and Justice Sandeep Mehta |
| Key issue | Difference between PTR and MRP of medicines |
| Example discussed | ₹2,700 PTR versus nearly ₹27,000 MRP |
| Price-control framework | Drugs (Prices Control) Order, 2013 |
| Retailer margin | 16% in the DPCO ceiling-price mechanism |
| Parent legislation | Essential Commodities Act, 1955 |
| Pricing regulator | National Pharmaceutical Pricing Authority |
| NPPA established | 1997 |
| Major concern | Affordability and excessive medicine markups |
| Wider issues | Generic medicines, medical devices and prescription practices |
